Gilead Sciences, Inc.

The UK’s originator drugs and generics industries are at odds over a rise in the clawbacks that companies must pay the government on the sales of branded medicines to the National Health Service under

German multinational Miltenyi Biotec’s senior leadership sees significant opportunities for India in the cell and gene therapy space if it can get things right in terms of shaping the regulatory frame

Real-world data (RWD) and real-world evidence (RWE) have the potential to help support companies in demonstrating the value of novel therapies to payers in Europe, particularly in the gene therapy spa

Tolebrutinib, Sanofi’s investigational treatment for non-relapsing secondary progressive multiple sclerosis (nrSPMS), is among the latest products that the European Medicines Agency has started review